Talphera Inc. (TLPH)

NASDAQ: TLPH · IEX Real-Time Price · USD
+0.150 (11.36%)
At close: Feb 23, 2024, 4:00 PM
+0.020 (1.36%)
After-hours: Feb 23, 2024, 7:48 PM EST

Company Description

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain.

Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.

The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain.

Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis.

The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection.

The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006.

AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.

Talphera Inc.
Talphera logo
Country United States
Founded 2005
IPO Date Feb 14, 2011
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 19
CEO Vincent Angotti

Contact Details

1850 Gateway Drive, Suite 175
San Mateo, California 94404
United States
Phone 650-216-3500

Stock Details

Ticker Symbol TLPH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001427925
CUSIP Number 00444T100
ISIN Number US00444T1007
SIC Code 2834

Key Executives

Name Position
Vincent J. Angotti Chief Executive Officer and Director
Dr. Pamela Pierce Palmer M.D., Ph.D. Co-Founder, Chief Medical Officer and Director
Raffi Mark Asadorian Chief Financial Officer
Lawrence G. Hamel Consultant
Anil N. Dasu Chief Engineering Officer

Latest SEC Filings

Date Type Title
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 EFFECT Notice of Effectiveness
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 424B7 Filing
Feb 6, 2024 S-3 Registration statement under Securities Act of 1933
Jan 29, 2024 D Notice of Exempt Offering of Securities
Jan 23, 2024 SC 13D General statement of acquisition of beneficial ownership
Jan 22, 2024 8-K Current Report
Jan 18, 2024 8-K Current Report
Jan 9, 2024 8-K Current Report